How to Turn Human Health Treatments into Blockbuster Veterinary Drugs

More and more companies are starting to licence their human-derived drugs to veterinary health companies, giving them an additional revenue stream for half the cost.

The path to market is considerably shorter and cheaper in Animal Health, meaning that instead of taking up to 15 years and $2.5 billion to get a human drug approved, the veterinary health route can take two thirds of the time at one twenty-fifth of the cost.

Kisaco Research's latest report looks at a selection of these human drugs that have hit the big-time within the animal health industry, with major benefits to both parties. View the report here.

Translating Human Medicine into Animal Health: Bulldozing the Misconceptions

External Innovation teams at animal health companies are eager to connect with innovators in human medicine and technology in order to tackle areas of unmet medical need that exist in veterinary medicine, but human biotechs are apprehensive about making this jump.

Kisaco Research interviewed tens of human biotech companies to discover what the most common misconceptions are and how we can overcome them. Read the full report here.

Want to Increase ROI? Collaborate with an Animal Health Company

The benefits for human biotech and veterinary medicine companies collaborating are vast — Kisaco Research have compiled a list of the top benefits to human biotech companies in their recent report here.

"Human health can benefit immensely from veterinary studies as many of the diseases seen in animals have a very similar etymology, time course and response to treatments as their human counterpart. Furthermore, development of veterinary therapeutics can be a faster and considerably less expensive path to clinical proof of concept. This can translate more rapidly to human studies."

- Michael G. Palfreyman, Director of the Scientific Advisory Board, Pafos Pharma, LLC: attendee at the Human Biotech & Animal Health Business Partnering Summit 2018

Pediatric, Veterinary Oncologists Call for More Comparative Research

For most people, there isn't an immediate connection between pediatric and canine cancer — unless you're an oncologist, or researcher, who works in either of these fields.

Then, the similarities are striking. Pediatric and canine cancer doctors, researchers, health advocates, government officials, and pharmaceutical leaders gathered in Washington, D.C. at the Paws for a Cure Summit, presented by the Canines-n-Kids Foundation, to talk about how they can better work together—in and outside the lab—so that advances can be made in both disease areas. Read the article here.
Merck Animal Health and XL-protein Partner to Produce Biopharmaceuticals for Animals

Following a nearly three-year research collaboration between XL-protein and MSD Animal Health (Merck Animal Health in the United States), the companies announced that they have inked a licensing agreement to develop biologics for animals. All of the product candidates in development have previously been used for human health medications, according to a press release announcing the partnership. Per the terms of the agreement, XL-protein will use its proprietary technology for plasma half-life extension, also known as its PASylation platform, to develop MSD Animal Health targets. MSD Animal Health will retain all of the rights to the drug candidates discovered through the collaboration. Read the article here.

Presented by:
 Pharmaceutical Technology


Sponsored by:
Dolomite